In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Actelion, Axovan develop GPCR drug candidates

Executive Summary

Actelion Ltd. (develops drugs that act on the endothelium) has licensed development and commercialization rights to molecules discovered by Axovan AG (G protein-coupled receptor drug targets). In a two-year project, Axovan will use its medicinal chemistry expertise to optimize the hits its GPCR screening platform identifies.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies